Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
NCT07830732· Phase 3· Novo Nordisk A/S· Source
Recruiting
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2026-526336-39-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source
Recruiting
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities
2026-526172-23-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source
Recruiting
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
NCT07506863· Phase 3· Agios Pharmaceuticals, Inc.· Source
Recruiting
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
NCT07834346· Phase 3· Hellenic Institute for the Study of Sepsis· Source
Recruiting
A Study for Comparing a Generic Combination of Brimonidine and Timolol Eye Drops versus Combigan® Eye Drops in the Treatment of Patients with Glaucoma
2025-523227-22-00· Phase 3· OmniVision GmbH· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
NCT07745504· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study to Evaluate a New Treatment Option for Helicobacter pylori Infection Compared to First Line Treatment.
2026-525291-26-00· Phase 3· Verisfield Single Member S.A.· Source
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371· Phase 3· Nektar Therapeutics· Source
Recruiting
A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
2025-524404-29-00· Phase 2· Eli Lilly & Co.· Source
Recruiting
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
NCT07326540· Phase 3· BioVersys SAS· Source
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections
2024-516216-16-00· Phase 3· Basilea Pharmaceutica International AG Allschwil· Source
Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702· Phase 2· AstraZeneca· Source
Recruiting
A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus
2024-520385-57-01· Phase 1· Climb Bio Inc.· Source
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
NCT07095127· Phase 2· Nuvig Therapeutics, Inc.· Source
Recruiting
Study to evaluate efficacy and safety of inclisiran in children aged 2 to under 12 years of age with homozygous familial hypercholesterolemia
2024-514595-41-00· Phase 3· Novartis Pharma AG· Source
Not yet recruiting
A Study to Learn About the Study Medicine Called Aztreonam-Avibactam in Neonates and Infants Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Bacteria
NCT06462235· Phase 2· Pfizer Inc.· Source
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226· Phase 3· Novo Nordisk A/S· Source
Recruiting
ALLIC 2022 international clinical investigation for advanced management of childhood acute lymphoblastic leukemia
2024-513824-41-00· Phase 4· Semmelweis University· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2024-512895-36-00· Phase 3· Akero Therapeutics Inc.· Source
Active, not recruiting
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus
2024-510584-37-00· Phase 2· Zenas Biopharma (USA) LLC· Source
Active, not recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168· Ipsen· Source
Active, not recruiting
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· Phase 2/3· St. Anna Childrens Cancer Research Institute GmbH· Source
Active, not recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383· Phase 4· Novo Nordisk A/S· Source
Active, not recruiting
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· Phase 3· AbbVie· Source
Active, not recruiting
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044· Phase 1/2· Amgen· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118· Phase 3· Sanofi· Source
Recruiting
Biomarker-Guided Early Clarithromycin Treatment To Prevent Sepsis Progression In Community-Acquired Pneumonia: The REACT Randomized Clinical Trial
2023-507295-40-00· Phase 3· Hellenic Institute For The Study Of Sepsis· Source
Terminated
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156· Phase 2· Sanofi· Source
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· Phase 3· AbbVie· Source
Terminated
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06028230· Phase 2· Sanofi· Source
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717· Phase 2/3· GlaxoSmithKline· Source
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617· Phase 3· Gilead Sciences· Source
Recruiting
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
NCT05693909· Phase 2· Pharmacosmos A/S· Source
Recruiting
Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients
NCT07642375· CareAcross· Source
Contact: Investigator
Active, not recruiting
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182· Phase 3· AbbVie· Source
Recruiting
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567· Phase 3· Takeda· Source
Recruiting
A Study of Aztreonam-Avibactam (ATM-AVI) Compared to Best Available Therapy in Pediatric Participants with Serious Gram-Negative Bacterial Complicated Intra-abdominal, Complicated Urinary Tract, Blood Stream Infections, and Hospital Acquired and Ventilator Associated Pneumonia
NCT05639647· Phase 2· Pfizer Inc.· Source
Showing 50 of 77.